The first paragraph summed it well - drastic price reduction would enable more breast cancer patients with HER2-positive to be treated with trastuzumab. Trastuzumab treatment is heavily subsidised for patients who fits certain criteria in government hospitals. For these patients, this news won't affect them. Who will it benefit then? Besides adhering to KKM drug … Continue reading Good News for Breast Cancer Patients with HER2-positive
Tag: breast cancer
A young lady in her early 40s had left breast cancer, pT2N2MO (stage III), ER positive, HER2 negative. She completed surgery, chemotherapy and radiotherapy. When I told her that she will need hormonal therapy for up to 10 years based on latest study, she said the study must be pharma-sponsored to encourage longer use of … Continue reading Early Breast Cancer: Importance of Hormonal Therapy in ER-positive Breast Cancer
Introduction International guidelines highly recommend adjuvant trastuzumab for breast cancer with HER2+; specifically, immunohistochemistry (IHC 3+, over expression) or fluorescence in situ hybridisation (FISH) amplified affect 20% of all breast cancer cases Addition of 1 year of adjuvant trastuzumab to adjuvant chemotherapy significantly improved disease- free survival (DFS) and overall survival (OS) among women with HER2+ breast … Continue reading Better Practice: 6 months vs 12 months Adjuvant Trastuzumab (Herceptin) in Early Breast Cancer
A young patient in her 30s was recently diagnosed with early breast cancer (stage 2). She was not keen for further adjuvant treatment as she was worried that it might affect her fertility and chances to get pregnant. She didn't even ask if it was safe for her to omit adjuvant treatment. There is one … Continue reading Early Breast Cancer: Will Treatments Affect My Chances To Get Pregnant?